Julie Ledgerwood
#50,599
Most Influential Person Now
American allergist and immunologist
Julie Ledgerwood's AcademicInfluence.com Rankings
Julie Ledgerwoodphilosophy Degrees
Philosophy
#10280
World Rank
#14071
Historical Rank
Logic
#8181
World Rank
#10195
Historical Rank
Download Badge
Philosophy
Julie Ledgerwood's Degrees
- Doctorate Medicine Johns Hopkins University
- PhD Immunology Stanford University
Why Is Julie Ledgerwood Influential?
(Suggest an Edit or Addition)According to Wikipedia, Julie E. Ledgerwood is an American allergist and immunologist, who is the chief medical officer and serves as chief of the Clinical Trials Program at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health in Bethesda, Maryland. She is a Doctor of Osteopathic Medicine.
Julie Ledgerwood's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (2020) (5634)
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) (2366)
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. (2019) (1061)
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (2020) (1020)
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates (2020) (809)
- Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine (2013) (693)
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (2020) (613)
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (2021) (505)
- Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection (2015) (380)
- Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. (2016) (344)
- A Recombinant Vesicular Stomatitis Virus Ebola Vaccine (2017) (333)
- Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody (2016) (329)
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. (2015) (295)
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase (2021) (278)
- Protection against malaria at 1 year and immune correlates following PfSPZ vaccination (2016) (277)
- Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera (2015) (275)
- Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo (2014) (243)
- Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses (2016) (241)
- Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 (2011) (240)
- Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV‐1 human monoclonal antibody VRC01 in healthy adults (2015) (214)
- Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial (2014) (213)
- Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials (2017) (210)
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination (2022) (202)
- A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. (2010) (202)
- Chimpanzee Adenovirus Vector Ebola Vaccine (2017) (192)
- Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial (2016) (190)
- DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials (2011) (189)
- Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection (2017) (188)
- Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. (2016) (188)
- Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages (2014) (181)
- A proof of concept for structure-based vaccine design targeting RSV in humans (2019) (170)
- Structural and molecular basis for Ebola virus neutralization by protective human antibodies (2016) (166)
- Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2018) (160)
- Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. (2021) (148)
- Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses (2010) (147)
- Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults (2018) (145)
- Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans (2017) (136)
- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants (2021) (133)
- A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. (2011) (129)
- Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. (2013) (119)
- Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial (2014) (107)
- Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial (2015) (103)
- Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial (2017) (96)
- Functional Interrogation and Mining of Natively-Paired Human VH:VL Antibody Repertoires (2017) (89)
- Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. (2019) (89)
- Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials (2017) (83)
- H5N1 Vaccine–Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem (2015) (82)
- Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (2019) (78)
- Preferential induction of cross-group influenza A hemagglutinin stem–specific memory B cells after H7N9 immunization in humans (2017) (70)
- Zika Virus Vaccine Development: Progress in the Face of New Challenges. (2019) (69)
- Vaccinate for the next H2N2 pandemic now (2011) (68)
- Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization (2021) (66)
- DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial (2013) (65)
- Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies (2021) (59)
- DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. (2013) (59)
- Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans (2012) (58)
- Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses (2017) (56)
- Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus (2014) (55)
- Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. (2020) (55)
- Mechanism and Significance of Cell Type-Dependent Neutralization of Flaviviruses (2014) (55)
- A Monoclonal Antibody for Malaria Prevention. (2021) (54)
- Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. (2013) (52)
- Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus–Specific CD8+ T Cells (2018) (50)
- Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. (2019) (50)
- A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. (2016) (47)
- Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions (2021) (46)
- Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. (2019) (45)
- Randomization to standard and concise informed consent forms: development of evidence-based consent practices. (2012) (43)
- Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults (2017) (40)
- The Zika virus envelope protein glycan loop regulates virion antigenicity. (2018) (40)
- Circulating CXCR5+CD4+ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines (2015) (37)
- A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. (2010) (37)
- Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants (2021) (35)
- DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases (2009) (32)
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants (2021) (29)
- A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies (2020) (29)
- Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial (2022) (29)
- Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus. (2016) (26)
- Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. (2015) (25)
- Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera (2018) (24)
- Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART (2018) (23)
- Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine. (2011) (23)
- Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults (2015) (23)
- Epitope-Specific Serological Assays for RSV: Conformation Matters (2019) (23)
- DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial (2018) (22)
- Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality (2020) (21)
- An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial (2017) (20)
- Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011) (2014) (20)
- DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial (2015) (18)
- Multiplexed FluoroSpot for the Analysis of Dengue Virus– and Zika Virus–Specific and Cross-Reactive Memory B Cells (2018) (18)
- Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial (2020) (17)
- Vaccine Development in the Twenty‐First Century: Changing Paradigms for Elusive Viruses (2009) (16)
- Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial (2019) (16)
- Progress with PfSPZ Vaccine, a radiation attenuated Plasmodium falciparum sporozoite vaccine (2014) (15)
- A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings (2021) (14)
- Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. (2022) (13)
- Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. (2015) (12)
- Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial (2022) (12)
- Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012) (2016) (12)
- Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody (2021) (11)
- P15-17. Social media as a tool for engaging and educating audiences around HIV vaccine research and clinical trial participation (2009) (11)
- Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. (2022) (11)
- Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor (2020) (10)
- Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort. (2015) (10)
- Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial (2019) (9)
- Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials (2021) (9)
- Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. (2022) (8)
- Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial (2014) (7)
- Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions (2020) (7)
- Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients (2021) (6)
- AS03-adjuvanted influenza vaccine in elderly people. (2013) (6)
- A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination (2022) (5)
- Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses. (2013) (5)
- A sensitive method to quantify HIV-1 antibodies in mucosal samples. (2021) (5)
- Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach (2020) (5)
- An introduction to the Marburg virus vaccine consortium, MARVAC (2022) (5)
- Correction: Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination (2016) (5)
- Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge (2021) (4)
- Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants (2021) (4)
- Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. (2021) (4)
- Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2019) (4)
- Limited flavivirus cross-reactive antibody responses elicited by a ZIKV DNA vaccine candidate in humans. (2021) (3)
- Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings (2022) (2)
- Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. (2019) (2)
- WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines, Geneva, Switzerland, December 2019 (2020) (2)
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis (2022) (2)
- Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention (2022) (2)
- Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial (2023) (2)
- Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial (2022) (1)
- An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans (2023) (1)
- Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes (2021) (1)
- WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines, Geneva, Switzerland, December 2019 (2020) (1)
- An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults (2023) (1)
- Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial. (2023) (1)
- P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen (2009) (1)
- P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011) (2009) (1)
- Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114: A Phase 1 Trial of a Therapeutic Monoclonal Antibody Targeting Ebola Virus Glycoprotein (2019) (1)
- Senescent Cells Block Cancer , Contribute to Aging (2019) (0)
- Optimization of the CIS43LS Malarial Monoclonal Antibody and Protection Against Malaria (2022) (0)
- Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials (2021) (0)
- Infusion Reactions in Persons Receiving the Broadly Neutralizing Antibody VRC01 or Placebo for Reduction of HIV-1 Acquisition: Results From the Phase 2b Antibody Mediated Prevention (AMP) Randomized Trials (2021) (0)
- T Cells + CD8 Specific - Antiviral Responses of Zika Virus Reveals Multifunctional and Cytotoxic Cutting Edge: Transcriptional Profiling (2018) (0)
- Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination (2023) (0)
- term goal of a universal vaccine provide great hope for a reduction in morbidity and mortality caused by infl uenza infection. (2013) (0)
- Progress with PfSPZ Vaccine, a radiation attenuated Plasmodium falciparum sporozoite vaccine (2014) (0)
- Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera (2018) (0)
- Neutralizing Activ ity of Zika Virus-Immune Sera Identifies a Single Viral Serotype Graphical (0)
- This information is current as in the Hemagglutinin Stem in the Recognition of a Neutralizing Epitope Genetically Constrained by the IGHV Locus Elicited Memory B Cells Are − H 5 N 1 Vaccine (2015) (0)
- Early Innate and Adaptive Immune Responses to Investigational Human Immunodeficiency Virus (HIV)-1 Vaccines (VRC 016 study) (2015) (0)
- Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2019) (0)
- Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2019) (0)
- P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults (2009) (0)
- An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial (2017) (0)
- Pharmacokinetics and predicted neutralization coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials (2020) (0)
- cAd3 Ebola Vaccine: Development and Phase I Clinical Trial Results (2015) (0)
- Safety and Immunogenicity of DNAVaccines Encoding Ebolavirus and Marburgvirus Wild- Type Glycoproteins in a Phase I Clinical Trial (2015) (0)
- VRC 311: Phase I Clinical Trial of a Virus-Like Particle Chikungunya Vaccine in Healthy Adults (2013) (0)
This paper list is powered by the following services:
Other Resources About Julie Ledgerwood
What Schools Are Affiliated With Julie Ledgerwood?
Julie Ledgerwood is affiliated with the following schools:
